NATALEE 6-year OS analysis shows modest (early…given what we just saw in NSABP42…) improvement in OS.

Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·2026-10-23 20:50· 2 天前评分70

正文 · 原文

NATALEE 6-year OS analysis shows modest (early…given what we just saw in NSABP42…) improvement in OS.
IDFS benefit persists over time. #ESMO26 @OncoAlert

502 浏览 · 8 赞 · 5 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：Stephanie Graff, MD, FACP, FASCO · x.com